Facebook Instagram X-twitter Linkedin Youtube Spotify Apple

Duchenne News Tags: Entrada Therapeutics

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Capricor Therapeutics Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco ITF Therapeutics NS Pharma PepGen Percheron Therapeutics Pfizer Pliant Therapeutics Precision Biosciences PTC Therapeutics REGENXBIO Roche Santhera Sarepta Therapeutics Satellos Bioscience Solid Biosciences Upsher-Smith Wave Life Sciences
September 21, 2023

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne

Entrada announces the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44...
Read More
August 7, 2023

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne

Entrada announces authorization for its CTIMP for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44
Read More
January 10, 2023

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne who are Exon 45 Skipping Amenable

Entrada announces the selection of a second clinical candidate within its Duchenne franchise, ENTR-601-45
Read More
December 21, 2022

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada announces clinical hold notice from U.S. FDA regarding IND for ENTR-601-44
Read More